



HAL
open science

Telacebec Interferes with Virulence Lipid Biosynthesis Protein Expression and Sensitizes to Other Antibiotics

Zhiyu Zhou, Ruddy Wattiez, Patricia Constant, Hedia Marrakchi, Karine Soetaert, Vanessa Mathys, Véronique Fontaine, Sheng Zeng

► **To cite this version:**

Zhiyu Zhou, Ruddy Wattiez, Patricia Constant, Hedia Marrakchi, Karine Soetaert, et al.. Telacebec Interferes with Virulence Lipid Biosynthesis Protein Expression and Sensitizes to Other Antibiotics. *Microorganisms*, 2023, 11 (10), pp.2469. 10.3390/microorganisms11102469 . hal-04291589

HAL Id: hal-04291589

<https://hal.science/hal-04291589v1>

Submitted on 20 Nov 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Article

Telacebec Interferes with Virulence Lipid Biosynthesis Protein Expression and Sensitizes to Other Antibiotics

Zhiyu Zhou ¹, Ruddy Wattiez ², Patricia Constant ³, Hedia Marrakchi ³, Karine Soetaert ⁴, Vanessa Mathys ⁴ ,
Véronique Fontaine ^{1,*} and Sheng Zeng ^{5,*}

¹ Microbiology, Bioorganic & Macromolecular Chemistry Research Unit, Faculté de Pharmacie, Université libre de Bruxelles (ULB), Boulevard du Triomphe, 1050 Brussels, Belgium; zhiyu.zhou@ulb.be

² Laboratory of Proteomics and Microbiology, Research Institute for Biosciences, University of Mons, Place du Parc 23, 7000 Mons, Belgium

³ Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III—Paul Sabatier (UT3), 31077 Toulouse, France

⁴ National Reference Laboratory “Mycobacterium”, Sciensano, 1180 Uccle, Belgium

⁵ School of Nursing and Health, Nanfang College Guangzhou, Guangzhou 510970, China

* Correspondence: veronique.fontaine@ulb.be (V.F.); zengsheng_myco@126.com (S.Z.)

Abstract: Tuberculosis (TB), caused by *Mycobacterium tuberculosis* (Mtb), remains a public health issue, particularly due to multi-drug-resistant Mtb. The bacillus is wrapped in a waxy envelope containing lipids acting as essential virulence factors, accounting for the natural antibiotic resistance of mycobacteria. Telacebec (previously known as Q203) is a promising new anti-TB agent inhibiting the cytochrome *bc*₁ complex of a mycobacterial electron transport chain (ETC). Here, we show that the telacebec-challenged *M. bovis* BCG exhibited a reduced expression of proteins involved in the synthesis of phthiocerol dimycocerosates (PDIMs)/phenolic glycolipids (PGLs), lipid virulence factors associated with cell envelope impermeability. Consistently, telacebec, at concentrations lower than its MIC, downregulated the transcription of a PDIM/PGL-synthesizing operon, suggesting a metabolic vulnerability triggered by the drug. The drug was able to synergize on BCG with rifampicin or vancomycin, the latter being a drug exerting a marginal effect on PDIM-bearing bacilli. Telacebec at a concentration higher than its MIC had no detectable effect on cell wall PDIMs, as shown by TLC analysis, a finding potentially explained by the retaining of previously synthesized PDIMs due to the inhibition of growth. The study extends the potential of telacebec, demonstrating an effect on mycobacterial virulence lipids, allowing for the development of new anti-TB strategies.

Keywords: *Mycobacterium bovis* BCG; telacebec; vancomycin; PDIMs; virulence lipids



Citation: Zhou, Z.; Wattiez, R.; Constant, P.; Marrakchi, H.; Soetaert, K.; Mathys, V.; Fontaine, V.; Zeng, S. Telacebec Interferes with Virulence Lipid Biosynthesis Protein Expression and Sensitizes to Other Antibiotics. *Microorganisms* **2023**, *11*, 2469. <https://doi.org/10.3390/microorganisms11102469>

Academic Editors: Roberta Colicchio, Mariateresa Vitiello and Chiara Pagliuca

Received: 7 September 2023

Revised: 26 September 2023

Accepted: 28 September 2023

Published: 30 September 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Tuberculosis (TB), caused by *Mycobacterium tuberculosis* (Mtb), remains the first leading cause of deaths from a single infectious agent. Among the 10.6 million people developing active TB in 2021, an estimated 450,000 patients suffered from multi-drug-resistant TB, which, by definition, is resistant to rifampicin and isoniazid, two of the core anti-TB drugs [1]. Drug-resistant TB remains an increasingly severe public threat as it is only curable with relatively limited effective drug options showing eventually severe side effects. Therefore, there is an urgent need to find more appropriate drug combinations, particularly based on novel anti-TB agents.

Mtb and the closely related vaccine strain *M. bovis* BCG (BCG) are obligate aerobic slow-growing mycobacteria producing their energy (i.e., ATP) predominantly through oxidative phosphorylation using the proton motive force generated in the electron transport chain (ETC) [2]. Mycobacterial ETC has received intensive attention, leading to the discovery of bedaquiline and telacebec (previously known as Q203). Telacebec, an imidazopyridine currently in clinical development, inhibits the cytochrome *bc*₁:*aa*₃ complex by binding

to the menaquinol-binding site of the QcrB subunit, forcing the bacilli to use the less energetically efficient cytochrome *bd* oxidase [3–6]. This ETC rerouting renders the activity of telacebec only bacteriostatic [6,7]. Recent work thus focused on the identification of novel agents targeting mycobacterial cytochrome *bd* oxidase, with the aim of fully inhibiting the ETC, with some promising results obtained [6,8,9]. The continuous identification of other telacebec-based drug combinations will benefit from a thorough understanding of mycobacterial adaptations, in response to telacebec.

Mycobacterial species such as Mtb and BCG, similarly harboring a waxy cell envelope containing phthiocerol dimycocerosates (PDIMs) and structurally related phenolic glycolipids (PGLs), are inherently resistant to numerous antibiotics, including vancomycin, a glycopeptide antibiotic targeting the peptidoglycan biosynthesis [10–12]. PDIMs and PGLs are two surface-exposed methyl-branched lipids that are only present in pathogenic mycobacteria and BCG [11,13,14]. Genes required for their synthesis and transport are clustered in a ~50-kilobase fragment of Mtb/BCG chromosome containing several transcriptionally coupled operons, including the *fadD26-papA5* operon [15,16]. The *fadD26-papA5* operon, starting from the *fadD26* gene, encodes proteins involved in PDIM/PGL synthesis and translocation, including FadD26, the PpsA-E and DrrA-C proteins [16]. Mycobacterial mutants with disruptions in the PDIM/PGL biosynthetic or transport pathway exhibit significantly impaired virulence [17,18], demonstrating that PDIMs/PGLs are important virulence factors. PDIMs not only promote mycobacterial macrophage entry, but also prevent phagosomal acidification, permeabilize phagosomal membranes in infected macrophages, and prompt bacillary dissemination by facilitating macrophage necrosis [14,18–20]. Importantly, PDIMs and PGLs also contribute to the cell envelope integrity [21]. We previously reported that in BCG and Mtb, loss of the lipids is linked to an impaired biofilm phenotype and heightened susceptibility to multiple antibiotics, including rifampicin and vancomycin [11,12]. Subversion of Mtb virulence and intrinsic antibiotic resistance was indeed observed using inhibitors of the PDIM/PGL synthetic pathway [10,22]. Identification of other drugs that could directly or indirectly affect PDIM/PGL production could boost the discovery of more effective treatment options for managing drug-resistant TB.

The aim of the study was to further investigate the potential of telacebec, through the proteomic analysis of the telacebec-treated BCG, a suitable and biosafe model organism to study Mtb escape mechanisms and antibiotic susceptibility. The proteomic analysis revealed a potential effect of telacebec on the mycobacterial production of PDIMs/PGLs, and we further explored whether the drug could synergize with other antibiotics, e.g., vancomycin and rifampicin.

2. Materials and Methods

2.1. BCG Strains

BCG GL2, a strain issued from the BCG Pasteur strain, was described previously [12]. The BCG strain was maintained in 7H9 medium supplemented with 0.05% Tween 80 and 10% albumin-dextrose-catalase (ADC) enrichment (Becton, Dickinson and Company, Franklin Lakes, NJ, USA).

2.2. Construction of the *pfadD26-luxAB* Plasmid

The *E. coli*/mycobacteria shuttle pSMT1 plasmid, harboring *Vibrio harveyi luxA* and *luxB* genes under the transcriptional control of the Mtb *cpn60.2* promoter and the hygromycin B resistance gene [23], was digested by *AleI* (14 bp upstream of P_{hsp60}) and *SnaBI* (87 bp downstream of the *luxB* start codon) to remove the original promoter P_{hsp60} , obtaining the vector. A 705 bp 5'-upstream region of *fadD26*, the first gene of the *fadD26-papA5* operon, was subjected to promoter prediction using BPROM (<http://softberry.com>, first accessed on 1 July 2018). Two inserts (A and B) were prepared for the subsequent In-Fusion Cloning. The insert A was the 705 bp upstream sequence before the first gene in the *fadD26-papA5* operon [15]. The insert B was the missing part (*luxA* plus 87 bp of *luxB*) of the *luxAB* gene after the enzymatic digestion of pSMT1. The inserts A and B were amplified

using, respectively, BCG genomic DNA and pSMT1 as templates. The primer pairs used for the PCRs are described in Table S1. The vector, insert A, and insert B were ligated via homologous recombination using an In-Fusion HD Cloning Kit (Takara, Shiga, Japan). The *pfadD26-luxAB*-transformed *E. coli*, resistant to hygromycin, were identified by PCR and verified subsequently by sequencing.

2.3. The *pfadD26-luxAB*-Transformed BCG

Fresh culture of BCG, at an optical density at 600 nm (OD_{600}) of 0.9, was harvested by centrifugation at $4000\times g$ for 10 min. To obtain competent BCG, the bacterial pellet was washed 4 times with 50, 25, 10, and 5 mL ice-cold 10% (*v/v*) glycerol, before final resuspension in 1–2 mL ice-cold 10% glycerol. The competent BCG was transformed by electroporation. Briefly, 500–1000 ng of plasmids were mixed with 200 μ L competent cells. The mixture was transferred to a 0.2 cm cuvette, followed by electroporation (EC_3 set to 3 kV for 5.5–6 msec) using a Bio-Rad electroporator. After electroporation, bacteria were allowed to recover for 12 h at 37 °C in 7H9/0.05% Tween 80/10% ADC without antibiotics, before plating on 7H11 agar with 50 μ g/mL hygromycin B.

2.4. Bioluminescence Detection

BCG harboring the *pfadD26-luxAB* plasmid was grown with 50 μ g/mL hygromycin B to an OD_{600} of 0.4–0.6, followed by treatment with telacebec and measurement of LuxAB activity. Briefly, 100 μ L of the freshly prepared substrate (18.8 μ L decanal in 10 mL ethanol, adapted from [23]) was injected into 900 μ L bacterial culture, and bioluminescence was measured using Lumat LB 9507 (Berthold) for 10 s.

2.5. Drug Susceptibility and Synergy Assessment

The BCG strain was grown at 37 °C in 7H9/0.05% Tween 80/10% ADC until OD_{600} reached 0.3–0.9. The macrodilution assay was performed in 12 mL screw-capped tubes containing 7H9 medium supplemented with 0.2% glycerol and 10%ADC, without Tween 80. Five hundred microliter inoculum diluted to reach an OD_{600} of 0.01 was added to 500 μ L serial drug dilutions in 7H9/0.02% glycerol/10% ADC. Tubes were placed at 37 °C without shaking. Growth was recorded on the day when the growth of the drug-free control containing 1/100 inoculum became visible, in order to assess the minimal inhibitory concentration (MIC, being the lowest drug concentration inhibiting >99% of bacterial growth) [10]. This experiment was performed three times to ascertain the reproducibility of the MIC assay. The fractional inhibitory concentration index (FICI) of telacebec in combination with vancomycin or rifampicin was calculated according to the formula $FICI = FIC_a + FIC_b = MIC_{ab}/MIC_a + MIC_{ba}/MIC_b$. The MIC of telacebec (MIC_a) and vancomycin/rifampicin alone (MIC_b), the MIC of telacebec in combination with a fixed vancomycin/rifampicin concentration (MIC_{ab}), and inversely the MIC of vancomycin/rifampicin in combination with a fixed telacebec concentration (MIC_{ba}) were obtained. In agreement with the checkerboard method, synergy was reached when FICI was under 0.5 [24].

2.6. Protein Extraction

The biomass of the heat-inactivated bacteria was prepared as previously described [25]. Bacteria were first lysed in 6 M guanidine HCl, 50 mM K_2HPO_4/KH_2PO_4 (pH 8.5), followed by ultrasonication (3×10 s, 20% amplitude; U50 IKA Technik). Fifty milligrams of the extracted proteins were reduced and alkylated. The proteins were recovered by acetone precipitation and digested with 0.005% (*w/v*) trypsin (Promega V5111, Madison, WI, USA) in 25 mM NH_4HCO_3 (pH 8.5). The trypsin treatment was stopped by 0.1% formic acid (*v/v*).

2.7. MS Analysis, SWATH Acquisition, and Data Interpretation

Prior to mass spectrometry (MS) analysis, reverse-phase chromatography was used to separate the extracts. The reverse-phase column (15 cm in length, 75 mm in diameter,

flow 300 nL/min; PepMap C18, Thermo Scientific Dionex, Waltham, MA, USA) was equilibrated with 4% (*v/v*) acetonitrile for 20 min, and peptide elution was carried out over an acetonitrile gradient from 4% to 35% (*v/v*) for 120 min. The separated peptides were then analyzed online by a TripleTOF 5600 mass spectrometer (AB Sciex, Framingham, MA, USA). Peptide spectra were acquired in data-dependent (DDA) and data-independent (DIA) acquisition modes. The MS/MS library was acquired in the DDA mode and analyzed by the ProteinPilot software (version 4.5, AB Sciex, USA) using the algorithm Paragon (version 4.5.0.0, AB Sciex, USA). Briefly, the trypsin was chosen as the cleavage specificity and alkylation (C) set to iodoacetamide, carbamidomethylation as fixed modifications, oxidation (M) and deamination (N, Q) as variable modifications were set. All biological modifications and amino acid substitutions were considered, and a thorough ID search was applied with peptide confidence set at 0.99. The raw spectral data obtained served as the input for ProteinPilot against the *Mycobacterium bovis* UniProt database. For the database search, the cut-off peptide confidence limit was set at 95%. ProteinPilot provided a global false discovery rate of 1% and a local false discovery rate of 5%. Accumulation time was set to 0.1 s for the MS1 scan and 65 ms for the MS2 scan, with the total cycle time being approximately 3.8 s.

For the SWATH analysis (DIA, AB Sciex), 32 incremental steps defined as windows of 25 *m/z* containing 1 *m/z* for the overlap of the window were passed over the full mass range (400–1250 *m/z*).

The peak intensity method was used for the quantitation of peptides. The ion chromatogram of the top six fragmented peptides was extracted, and their area was integrated over 15 min on six transitions. The tolerance was set at 100 ppm. The SWATH data were processed with the PeakView software (version 2.1.0.11041, AB Sciex, USA). The retention time was calculated manually from a group of 15 selected peptides with retention time in the range of 20–100 min. MarkerView Software (version 1.2.1, AB Sciex, USA) was used for the analysis of the relative abundance of the peptides. For all experiments, proteins identified with one peptide were rejected for interpretation. Only protein hits with a significant difference ($p < 0.05$) and a fold change of <0.83 or >1.2 were further analyzed [26,27]. Protein identities could be found using the UniProt entry number at <http://www.uniprot.org/>. Protein function annotations and categories were based on UniProt (<http://www.uniprot.org/>, first accessed on 10 September 2022), Mycobrowser (<https://mycobrowser.epfl.ch/>, accessed on 12 September 2022), and/or the NCBI Conserved Domain Search tool (<https://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml>, accessed on 10 September 2022). In addition, NCBI BLAST (<https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins>, accessed on 12 September 2022) was applied to find homology proteins in Mtb for the identified BCG proteins.

2.8. Lipid Analysis

Bacteria were treated or not with telacebec at 50 nM ($10 \times \text{MIC}$) for 2 days before being heat-inactivated. Lipids were then extracted twice with $\text{CHCl}_3/\text{CH}_3\text{OH}$ (1:2 *v/v*), then (2:1 *v/v*), concentrated under vacuum, washed two times with water, and dried. The total lipid extracts were then solubilized in CHCl_3 at 20 mg/mL. The DIM content of each extract (25 μL) was analyzed by thin-layer chromatography (TLC) on silica gel G 60 plates using petroleum ether/diethyl ether (9:1 *v/v*) as the eluent. Lipid compounds were visualized by spraying the plates with 10% phosphomolybdic acid in ethanol and heating. DIMs purified from Mtb were run as the control.

2.9. Statistical Analysis

The unpaired *t*-test was applied for comparisons between two groups (for the proteomic analysis). A *p*-value of <0.05 was considered statistically significant. The graphs were prepared with OriginPro 8 (OriginLab Corporation, Northampton, MA, USA) or with GraphPad Prism version 9.5.1 for Windows (GraphPad Software, San Diego, CA, USA).

3. Results

3.1. Decreased Abundance of Proteins Required for PDIM/PGL Synthesis by Telacebec

We treated BCG with 10 nM telacebec ($2 \times \text{MIC}$), showing only a bacteriostatic effect [7]. The proteomic analysis of the untreated and telacebec-treated BCG (at an early time point, 7 h) allowed for highlighting that 15 and 26 proteins were upregulated and downregulated, respectively, by telacebec (Figure 1). Six proteins categorized in the “intermediary metabolism and respiration” group were among the downregulated proteins (e.g., UreB (0.15-fold) and GalK (0.56-fold)), while 3 were found in the upregulated proteins (e.g., PckA (1.3-fold) and Lat (2.8-fold)) (Figure 1A–C). Among the upregulated proteins, at least 5 play a role in virulence, including EspD (1.7-fold), HspX (1.7-fold), PhoR (1.25-fold), MprA (1.4-fold), and Lat (2.8-fold) (Table 1). Notably, among the upregulated proteins, only 1 was involved in “lipid metabolism” (i.e., Tgs1, 1.3-fold). In contrast, 7 proteins grouped in “lipid metabolism” were identified in the downregulated proteins (Figure 1A,B), suggesting a general downregulation of lipid metabolism by telacebec. Among the proteins involved in “lipid metabolism”, 6 are associated with lipid biosynthesis (i.e., Fas, FadD22, AccD6, FadD26, FadD29, and PpsB; see red dots/triangles in Figure 1C), especially in PDIM/PGL biosynthesis (i.e., FadD22, FadD26, FadD29, and PpsB, all downregulated by telacebec; see red triangles in Figure 1C) (Table 1). FadD26 and PpsB are expressed from the *fadD26-papA5* operon, and FadD22/FadD29 from another. Other proteins expressed from the operons were not identified in our proteomic assay. Hence, telacebec may interfere with the production of PDIMs/PGLs, important virulence factors associated with the cell envelope impermeability of the pathogenic slow-growing mycobacteria.

3.2. Telacebec Decreased the *fadD26* Promoter Activity

We further assessed the expression of the *fadD26-papA5* operon, as representative PDIM/PGL-synthesizing gene loci. The transcriptional activity of the first promoter of this operon, upstream to the *fadD26* gene, was investigated using a luciferase reporter system (Figure 2A) [15]. We constructed the *pfadD26-luxAB* plasmid containing the *luxAB* luciferase genes from *Vibrio harveyi* in the pSMT1 vector [23]. A 705 bp 5'-upstream region of the *fadD26* gene, predicted to harbor 2 putative promoter sites using the BPROM software (<http://softberry.com>, accessed on 1 July 2018) and reported to contain 2 transcriptional start sites (TSS) (Figure 2A), was inserted in the pSMT1 vector to replace the original mycobacterial *cpn60.2* promoter to control the *luxAB* transcription [23,28]. The luciferase activity obtained in the *pfadD26-luxAB*-transformed BCG showed high RLU values, demonstrating a strong promoter activity (Figure 2B). This activity was strongly reduced after 24 h telacebec treatment, depending on the telacebec concentration, achieving a 2- to 12-fold reduction. Notably, 1.25 nM telacebec (1/4 of the MIC) already decreased the promoter activity (Figure 2B), suggesting that the effect on PDIMs/PGLs occurs before the inhibition of bacillary growth. This effect was observed after 7 h treatment (Figure 2C), in agreement with our proteomic data showing a decreased level of proteins encoded in the operon.

3.3. Telacebec Synergized with Vancomycin and Rifampicin

We previously showed that PDIMs are required to reduce vancomycin susceptibility in both *Mtb* and BCG [12]. Moreover, loss of PDIMs also increases mycobacterial susceptibility to other antibiotics, such as rifampicin [12,29]. The reduced level of proteins required for PDIM/PGL synthesis (Table 1) and the decreased *fadD26* promoter activity (Figure 2) following telacebec treatment could suggest a potentiating effect of telacebec on other antibiotic susceptibility. This was investigated by the macrodilution method on BCG. In the presence of vancomycin (5 $\mu\text{g}/\text{mL}$, far below the MIC), the MIC of telacebec fell from 5 nM (without vancomycin) to 1.25 nM, while in the presence of a fixed amount of telacebec (1.25 nM), the MIC of vancomycin fell from $>200 \mu\text{g}/\text{mL}$ (without telacebec) to 5 $\mu\text{g}/\text{mL}$ (Table 2). Likewise, in the presence of rifampicin (0.0625 $\mu\text{g}/\text{mL}$), the MIC of telacebec fell from 5 nM (alone) to 1.25 nM, while in the presence of a fixed amount

of 1.25 nM telacebec, the MIC of rifampicin fell from 0.5 µg/mL (without telacebec) to 0.0625 µg/mL (Table 3). The calculation of FICI, showing values below 0.5 for both combinations, telacebec/vancomycin and telacebec/rifampicin, demonstrated that telacebec synergized with vancomycin and with rifampicin.

Table 1. Proteomic profiling of BCG treated with 10 nM telacebec for 7 h.

	BCG Homology Proteins in H37Rv	Name	Description	p-Value	Fold Change (Telacebec/Control)
Cell wall biosynthesis and cell process	Rv2950c	FadD29	Long-chain-fatty-acid-AMP ligase	0.02887	0.677371423
	Rv2247	AccD6	Acetyl-/propionyl-CoA carboxylase subunit beta	0.03024	0.641045938
	Rv2930	FadD26	Fatty-acid-AMP ligase	0.03297	0.685370986
	Rv3130c	Tgs1	Diacylglycerol O-acyltransferase	0.03431	1.258329713
	Rv2524c	Fas	Fatty acid synthase	0.03723	0.754112466
	Rv2932	PpsB	Phthiocerol synthesis polyketide synthase type I	0.03774	0.755835038
	Rv2190c	RipC	Peptidoglycan peptidase	0.00146	0.214892227
	Rv3484	CpsA2	Polysaccharide transfer to peptidoglycan	0.00653	0.789836749
	Rv3835	NA	Hypothetical protein in the cell wall	0.00786	0.212690355
	Rv3915	NA	Peptidoglycan hydrolase	0.01965	0.664403424
Metabolic pathways	Rv0211	PckA	Phosphoenolpyruvate carboxykinase	0.00217	1.294218998
	Rv0620	GalK	Galactokinase	0.01055	0.566918099
	Rv3308	PmmB	Phosphomannomutase; converts D-mannose 1-phosphate to D-mannose 6-phosphate	0.0301	0.196754059
	Rv3600c	NA	Type III pantothenate kinase catalyzing the phosphorylation of pantothenate, the first step in CoA biosynthesis	0.04899	0.086255116
	Rv1589	BioB	Biotin synthetase	0.01568	0.681640846
	Rv0991c	NA	Redox-regulated molecular chaperone	0.00875	0.693003332
	Rv0758	PhoR	Two-component system response sensor kinase	0.0358	1.247705251
Virulence	Rv0485	NA	Transcriptional regulator of pe13 and ppe18 gene pair	0.04811	0.497470112
	Rv0981	MprA	Two-component response regulator	0.04824	1.407815183
	Rv2031c	HspX	Alpha-crystallin	0.00824	1.749009088
	Rv0726c	NA	Possible methyltransferase associated with isoniazid resistance	0.00699	0.547160643
	Rv3867 Rv3614c	EspH EspD	ESX-1 secretion-associated protein ESX-1 secretion-associated protein	0.04805 0.03731	0.625076945 1.704031265
DNA/RNA metabolism	Rv1629	PolA	DNA polymerase I	0.01742	1.338907985
	Rv1641	InfC	Initiation factor IF-3	0.03486	0.725560396
	Rv3731	LigC	DNA ligase C	0.00194	4.862120018
Others	Rv1287	NA	HTH-type transcriptional regulator	0.02526	2.906914209
	Rv3200c	NA	Transmembrane cation transporter	0.01681	2.480604421
	Rv1072	NA	Transmembrane protein	0.0353	1.432802446
	Rv1849	UreB	Urease subunit beta	0.00076	0.150994385
	Rv3011c	GatA	Glutamyl-tRNA amidotransferase subunit A	0.04319	0.738761056
	Rv3290c	Lat	L-lysine-epsilon aminotransferase; catalytic activity: L-lysine + 2-oxoglutarate = 2-aminoadipate 6-semialdehyde + L-glutamate	0.04644	2.83040088

NA: not applicable.




Figure 1. Proteomic profiling of BCG treated with 10 nM telacebec for 7 h. (A,B) Functional category analysis of the upregulated (A) and downregulated (B) proteins was performed based on Mycobrowser (<https://mycobrowser.epfl.ch/>, first accessed on 12 September 2022). For each classification, the number of proteins (in bracket) and the percentages are shown. (C) Volcano plot showing downregulated (upper left) and upregulated (upper right) proteins in the treated bacilli as compared with the untreated control. Each dot/triangle (in grey, red or blue color) indicates a different protein. Names of particular proteins are given (see blue dots). Proteins required for lipid metabolism are emphasized by red dots/triangles, with those involved in PDIM biosynthesis indicated by triangles. The dot line parallel to the x-axis indicates a y value of 1.301 (i.e., $-\log_{10} 0.05$). The two dot lines parallel to the y-axis indicate x values of -0.263 (i.e., $\log_2 0.833$) and 0.263 (i.e., $\log_2 1.2$), respectively.

Table 2. Synergy between telacebec and vancomycin.

Treatment	MIC/FIC/FICI	
	Vancomycin ($\mu\text{g/mL}$)	Telacebec (nM)
Alone	>200/-/-	5/-/-
+Telacebec (nM)	5/<0.025/<0.275	-/-/-
+Vancomycin ($\mu\text{g/mL}$)	-/-/-	1.25/<0.25/<0.275




Figure 2. Telacebec decreased the *fadD26* promoter activity. (A) Characterization of the *fadD26* promoter region. The annealing site for the forward primer used to amplify the 705 bp upstream of the *fadD26* gene is colored (yellow). The reverse primer annealed just before the start of *fadD26*. The two predicted -35 and -10 elements are boxed. TSS: transcriptional start site. The two TSSs (indicated by arrows) were described previously [28]. Gene names were based on Mtb H37Rv. (B) Exponential *pfadD26*-luxAB-transformed BCG cultures were treated with indicated concentrations of telacebec for 24 h, followed by RLU measurement. The data were normalized by dividing by OD₆₀₀. (C) Exponential *pfadD26*-luxAB-transformed BCG cultures were treated with 10 nM telacebec for the indicated time points, followed by RLU measurement. The data were normalized by dividing by OD₆₀₀. The *fadD26* promoter activity was already decreased after 7 h of telacebec treatment.

Table 3. Synergy between telacebec and rifampicin.

Treatment	MIC/FIC/FICI	
	Rifampicin (µg/mL)	Telacebec (nM)
Alone	0.5/-/-	5/-/-
+Telacebec (nM)	0.0625/0.125/0.375	-/-/-
+Rifampicin (µg/mL)	-/-/-	1.25/0.25/0.375

To investigate whether the synergy could be due to a potential effect of telacebec on PDIM production, TLC analysis was performed. Relative to control, the telacebec (10 × MIC)-treated BCG did not show a detectable decrease in PDIM amount (Figure 3A). However, based on the data, the effect of telacebec on PDIM production could not be negated as this concentration of telacebec could expectedly inhibit the growth of the bacilli, potentially leading to the retaining of previously synthesized cell wall PDIMs (Figure 3B).




Figure 3. TLC analysis for the detection of PDIM amount in telacebec-treated BCG. **(A)** BCG was treated or not with telacebec (50 nM) for 2 days, followed by TLC analysis of the extracted lipids. DIM: DIMs purified from Mtb were run as a control. The experiment was performed twice, each in triplicate and one representative data shown. **(B)** The red/blue bars mark individual mycobacterial cells, and the number of bars indicates bacillary growth (increasing number for red bars) or not (same number for blue bars). In the synergy assay, the concentration of telacebec is 1/4 of the MIC (i.e., 1.25 nM), failing to inhibit the bacillary growth but already decreasing the *fadD26* promoter activity. In contrast, in the TLC analysis, a much higher growth-inhibiting concentration of telacebec was used.

4. Discussion

4.1. Effect of Telacebec on PDIMs: A Point of Metabolic Vulnerability

Telacebec, currently in clinical trials, inhibits the cytochrome *bc*₁/*aa*₃ route, leading to respiratory rerouting through the alternative cytochrome *bd* oxidase pathway [30]. This rerouting results in a rapid and significant decrease in cellular ATPs [8,30]. Mycobacterial exposure to bedaquiline, likewise inhibiting the ATP production in the respiratory chain, could trigger multiple metabolic vulnerabilities (e.g., glutamine synthetase) that can be leveraged for designing synergistic drug combinations [31,32]. However, a picture of metabolic vulnerabilities as a consequence of telacebec treatment has yet to be uncovered. Here, we show that telacebec interferes with the mycobacterial production of virulence lipids, PDIMs, allowing for potentiating vancomycin and rifampicin.

The over-representation of downregulated proteins involved in lipid metabolism in the telacebec-treated bacilli could be linked to the fact that the drug markedly decreases ATPs, indispensable for the energy-consuming lipid biosynthetic pathway [7,33]. Lupien et al. observed that in Mtb treated with another cytochrome *bc*₁ inhibitor, genes involved in lipid metabolism were over-represented in the downregulated gene set [34], suggesting a similar phenotype in the pathogenic mycobacteria. Proteins (e.g., FadD22, FadD26, FadD29, and PpsB) required for the PDIM/PGL biosynthesis, as well as the transcriptional activity of the *fadD26-papA5* operon, were downregulated quickly by telacebec, even at concentrations lower than the MIC. Hence, the effect of telacebec on PDIMs/PGLs seems to occur before the drug-induced growth stasis. In agreement, the nutrient-starved Mtb, producing lower ATPs, also downregulated the expression of genes required for the PDIM/PGL synthesis [35,36]. Moreover, the bedaquiline-treated Mtb also downregulated the expression of proteins involved in lipid metabolism, mostly in the biosynthesis of mycolic acids and PDIMs/PGLs [37]. Hence, the decreased biosynthesis of PDIMs/PGLs, part of a lipid reprogramming program, seems to be a general adaptive strategy employed by the stressed bacilli producing prominently reduced ATPs. How the PDIM/PGL biosynthesis could quickly respond to and coordinate with the extracellular stresses remains to be investigated.

PDIMs and PGLs, the two structurally related methyl-branched lipid esters, are non-covalently associated with the outer membrane of the pathogenic Mtb, of *M. marinum*, of *M. bovis*, and of BCG [12,14,15,38]. The two lipids, particularly PDIMs, contribute to cell envelope impermeability required for mycobacterial natural antibiotic resistance, in both the attenuated BCG and the pathogenic Mtb [12,15,39]. In the present study, the vaccine strain, BCG, was used for biosafety reasons. BCG and Mtb, sharing ~98% identity of their genomes [40], respond to stresses, generally, in a similar pattern. For instance, both organisms quickly and significantly decreased cellular ATP production and reduced their growth rates in response to telacebec [7,8]. To the best of our knowledge, the transcriptomic or proteomic data of the telacebec-treated mycobacteria (including Mtb) have not been reported before. It may be questioned whether the finding that telacebec could interfere with BCG PDIMs can be extended to Mtb. We note that treatment of Mtb H37Ra with TB47, another cytochrome *bc*₁ inhibitor [8], downregulated the expression of proteins involved in PDIM biosynthesis (unpublished observations). Furthermore, the ATP-depleting bedaquiline also decreases the Mtb expression of proteins involved in the synthesis of lipids, particularly PDIMs [37]. We previously reported that like BCG, Mtb deficient for PDIMs is hypersensitive to vancomycin [12]. Hence, it is reasonable to extrapolate that telacebec could also interfere with PDIM production in Mtb and hence potentiate rifampicin and vancomycin in the pathogenic bacilli.

More importantly, PDIMs/PGLs may exert functions far beyond maintaining cell envelope integrity, as demonstrated by their involvement in modulating the bacillary life cycle and in mycobacterial virulence [14,19,20,41]. Considering this, the *in vivo* anti-TB efficacy of telacebec may be even more potent. Indeed, a phase 2 clinical trial found that telacebec shows an early bactericidal activity when used to treat newly diagnosed pulmonary TB patients, as indicated by the gradual reductions in bacterial sputum load [42]. Hence, the PDIM/PGL downregulation, potentially responding to lower ATPs, may be considered a point of telacebec-induced metabolic vulnerabilities, which could be further targeted by the host immune responses and by other therapeutic agents. Previous work has revealed several points of metabolic vulnerability induced by the ETC-targeting bedaquiline, such as glycolytic vulnerability and glutamine synthetase vulnerability [31,32], resulting in the formation of more effective bedaquiline-based drug combinations.

Unexpectedly, the TLC analysis did not show a significant loss of cell wall PDIMs in telacebec-treated bacilli, a finding seemingly contradictory to our data obtained in the proteomic and promoter analysis. This could be explained by a potential effect of growth on previously synthesized PDIMs (Figure 3B). In the drug synergy assay, the telacebec concentration is 1/4 of the MIC (i.e., 1.25 nM), a concentration failing to inhibit the bacillary growth but already decreasing the *fadD26* promoter activity (Figure 2). Hence, a gradual loss of cell wall PDIMs can be expected as a result of active growth, eventually leading to the heightened susceptibility to vancomycin/rifampicin. In stark contrast, a significantly higher concentration of telacebec used in the TLC analysis is expected to inhibit the bacterial growth, potentially leading to the retaining of cell wall PDIMs that were synthesized before the addition of telacebec (Figure 3B). Detection of newly synthesized PDIMs, such as by the addition of a radio-labelled precursor (e.g., ¹⁴C propionate) just after the addition of telacebec, may provide a definitive answer.

4.2. Other Proteomic Signatures by Telacebec

Proteomic analysis also identified changes of several other proteins. For instance, the analysis identified proteins involved in bacterial growth and cell division, such as the ZipA-like protein Rv3835 (0.2-fold) potentially involved in the septum formation [43] and the Rv2190c protein (RipC, 0.2-fold), a peptidoglycan peptidase required for *Mtb* active growth [44,45]. In addition, two proteins expressed in the dormancy regulon (also known as the DosR regulon), i.e., Tgs1 (1.26-fold) and HspX (1.75-fold), were induced by telacebec (Figure 1C). The DosR regulon, comprising nearly 50 genes, is activated in response to multiple stresses, such as hypoxia, and its activation contributes to mycobacterial survival and antibiotic

tolerance [46–48]. Bedaquiline treatment also activates the DosR regulon in Mtb [37], suggesting a similar mycobacterial adaptation strategy in response to these ETC-targeting agents.

The proteomic analysis also gave additional interesting information. Rv3600c, a putative pantothenate kinase involved in the coenzyme A (CoA) biosynthetic pathway [49], was the most downregulated (0.086-fold) by telacebec (Figure 1C). This protein is expressed from a putative operon containing genes coding for PanC and PanD, two proteins participating in the biosynthesis of pantothenate, a CoA precursor [50]. Knowing that the cofactor CoA or pantothenate is required for lipid biosynthesis by polyketide synthesis proteins [51], such as the Pps proteins involved in PDIM/PGL biosynthesis, this observation could further highlight the impact of telacebec on PDIM/PGL biosynthesis. Intriguingly, the downregulation of Rv3600c was not previously identified by other cytochrome *bc*₁ inhibitors [34,52].

4.3. Conclusions

In conclusion, telacebec interferes with virulence lipid (PDIMs/PGLs) biosynthesis protein expression, considered as a point of the drug-induced metabolic vulnerabilities that could be further exploited for, at least, antibiotic potentiation. The finding expands the potential of telacebec, likely also other ATP-interfering agents, and opens up an avenue for formulating telacebec-based rational drug combinations. For instance, the synergistic combination of telacebec and vancomycin (poor oral bioavailability) could be further assessed for its anti-TB efficacy in animal TB models, followed by formulating dry powders for inhalation or by employing efficient delivery systems to achieve optimal pulmonary administration of the drug combination, a potential strategy for treating drug-resistant pulmonary TB patients.

Supplementary Materials: The following supporting information can be downloaded at <https://www.mdpi.com/article/10.3390/microorganisms11102469/s1>, Table S1: Primers used in the study; Excel file: Proteomic profiling of BCG treated with 10 nM telacebec for 7 h.

Author Contributions: Formal analysis, Z.Z., R.W., P.C., H.M., V.M., V.F. and S.Z.; investigation, Z.Z., K.S. and S.Z.; methodology, Z.Z., R.W., P.C., H.M., K.S., V.M., V.F. and S.Z.; resources, V.F. and S.Z.; validation, Z.Z., R.W. and P.C.; writing—original draft, Z.Z., V.F. and S.Z.; writing—review and editing, R.W., P.C., H.M., K.S., V.M., V.F. and S.Z. All authors have read and agreed to the published version of the manuscript.

Funding: The study was funded by a research startup fund granted by Nanfang College Guangzhou to S.Z. (2021BQ011) and by Guangdong Basic and Applied Basic Research Foundation to S.Z. (2023A1515012220). Z.Z. was funded by the China Scholarship Council (201908210292). The bioprofiling platform used for proteomic analysis was supported by the European Regional Development Fund and the Walloon Region, Belgium.

Data Availability Statement: Data supporting the reported results are available from the corresponding author upon request.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. WHO. *Global Tuberculosis Report 2022*; World Health Organization: Geneva, Switzerland, 2022.
2. Cook, G.M.; Hards, K.; Vilcheze, C.; Hartman, T.; Berney, M. Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria. *Microbiol. Spectr.* **2014**, *2*, 389–409. [CrossRef]
3. Pethe, K.; Bifani, P.; Jang, J.; Kang, S.; Park, S.; Ahn, S.; Jiricek, J.; Jung, J.; Jeon, H.K.; Cechetto, J.; et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. *Nat. Med.* **2013**, *19*, 1157–1160. [CrossRef]
4. Yanofsky, D.J.; Di Trani, J.M.; Krol, S.; Abdelaziz, R.; Bueler, S.A.; Imming, P.; Brzezinski, P.; Rubinstein, J.L. Structure of mycobacterial CIII(2)CIV(2) respiratory supercomplex bound to the tuberculosis drug candidate telacebec (Q203). *Elife* **2021**, *10*, e71959. [CrossRef]
5. Zhou, S.; Wang, W.; Zhou, X.; Zhang, Y.; Lai, Y.; Tang, Y.; Xu, J.; Li, D.; Lin, J.; Yang, X.; et al. Structure of *Mycobacterium tuberculosis* cytochrome *bcc* in complex with Q203 and TB47, two anti-TB drug candidates. *Elife* **2021**, *10*, e69418. [CrossRef]
6. Lee, B.S.; Hards, K.; Engelhart, C.A.; Hasenoehrl, E.J.; Kalia, N.P.; Mackenzie, J.S.; Sviriaeva, E.; Chong, S.M.S.; Manimekalai, M.S.S.; Koh, V.H.; et al. Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant *Mycobacterium tuberculosis*. *EMBO Mol. Med.* **2021**, *13*, e13207. [CrossRef]

7. Zeng, S.; Soetaert, K.; Ravon, F.; Vandeput, M.; Bald, D.; Kauffmann, J.M.; Mathys, V.; Wattiez, R.; Fontaine, V. Isoniazid Bactericidal Activity Involves Electron Transport Chain Perturbation. *Antimicrob. Agents Chemother.* **2019**, *63*, e01841–18. [[CrossRef](#)]
8. Zeng, S.; Zhang, J.; Sun, M.; Zhang, X.; Cook, G.M.; Zhang, T. Nitric Oxide-Dependent Electron Transport Chain Inhibition by the Cytochrome *bc₁* Inhibitor and Pretomanid Combination Kills *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* **2021**, *65*, e0095621. [[CrossRef](#)]
9. Jeffreys, L.N.; Ardrey, A.; Hafiz, T.A.; Dyer, L.A.; Warman, A.J.; Mosallam, N.; Nixon, G.L.; Fisher, N.E.; Hong, W.D.; Leung, S.C.; et al. Identification of 2-Aryl-Quinolone Inhibitors of Cytochrome *bd* and Chemical Validation of Combination Strategies for Respiratory Inhibitors against *Mycobacterium tuberculosis*. *ACS Infect. Dis.* **2023**, *9*, 221–238. [[CrossRef](#)]
10. Rens, C.; Laval, F.; Daffe, M.; Denis, O.; Frita, R.; Baulard, A.; Wattiez, R.; Lefevre, P.; Fontaine, V. Effects of Lipid-Lowering Drugs on Vancomycin Susceptibility of Mycobacteria. *Antimicrob. Agents Chemother.* **2016**, *60*, 6193–6199. [[CrossRef](#)]
11. Zeng, S.; Constant, P.; Yang, D.; Baulard, A.; Lefevre, P.; Daffe, M.; Wattiez, R.; Fontaine, V. Cpn60.1 (GroEL1) Contributes to Mycobacterial Crabtree Effect: Implications for Biofilm Formation. *Front. Microbiol.* **2019**, *10*, 1149. [[CrossRef](#)]
12. Soetaert, K.; Rens, C.; Wang, X.M.; De Bruyn, J.; Laneelle, M.A.; Laval, F.; Lemassu, A.; Daffe, M.; Bifani, P.; Fontaine, V.; et al. Increased Vancomycin Susceptibility in Mycobacteria: A New Approach To Identify Synergistic Activity against Multidrug-Resistant Mycobacteria. *Antimicrob. Agents Chemother.* **2015**, *59*, 5057–5060. [[CrossRef](#)] [[PubMed](#)]
13. Dulberger, C.L.; Rubin, E.J.; Boutte, C.C. The mycobacterial cell envelope—A moving target. *Nat. Rev. Microbiol.* **2020**, *18*, 47–59. [[CrossRef](#)] [[PubMed](#)]
14. Cambier, C.J.; Banik, S.M.; Buonomo, J.A.; Bertozzi, C.R. Spreading of a mycobacterial cell-surface lipid into host epithelial membranes promotes infectivity. *Elife* **2020**, *9*, e60648. [[CrossRef](#)] [[PubMed](#)]
15. Camacho, L.R.; Constant, P.; Raynaud, C.; Laneelle, M.A.; Triccas, J.A.; Gicquel, B.; Daffe, M.; Guilhot, C. Analysis of the phthiocerol dimycocerosate locus of *Mycobacterium tuberculosis*. Evidence that this lipid is involved in the cell wall permeability barrier. *J. Biol. Chem.* **2001**, *276*, 19845–19854. [[CrossRef](#)]
16. De Majumdar, S.; Sikri, K.; Ghosh, P.; Jaisinghani, N.; Nandi, M.; Gandotra, S.; Mande, S.; Tyagi, J.S. Genome analysis identifies a spontaneous nonsense mutation in *ppsD* leading to attenuation of virulence in laboratory-manipulated *Mycobacterium tuberculosis*. *BMC Genom.* **2019**, *20*, 129. [[CrossRef](#)]
17. Cox, J.S.; Chen, B.; McNeil, M.; Jacobs, W.R., Jr. Complex lipid determines tissue-specific replication of *Mycobacterium tuberculosis* in mice. *Nature* **1999**, *402*, 79–83. [[CrossRef](#)]
18. Osman, M.M.; Pagan, A.J.; Shanahan, J.K.; Ramakrishnan, L. *Mycobacterium marinum* phthiocerol dimycocerosates enhance macrophage phagosomal permeabilization and membrane damage. *PLoS ONE* **2020**, *15*, e0233252. [[CrossRef](#)]
19. Astarie-Dequeker, C.; Le Guyader, L.; Malaga, W.; Seaphanh, F.K.; Chalut, C.; Lopez, A.; Guilhot, C. Phthiocerol dimycocerosates of *M. tuberculosis* participate in macrophage invasion by inducing changes in the organization of plasma membrane lipids. *PLoS Pathog.* **2009**, *5*, e1000289. [[CrossRef](#)]
20. Quigley, J.; Hughitt, V.K.; Velikovskiy, C.A.; Mariuzza, R.A.; El-Sayed, N.M.; Briken, V. The Cell Wall Lipid PDIM Contributes to Phagosomal Escape and Host Cell Exit of *Mycobacterium tuberculosis*. *MBio* **2017**, *8*, e00148–17. [[CrossRef](#)]
21. Mohandas, P.; Budell, W.C.; Mueller, E.; Au, A.; Bythrow, G.V.; Quadri, L.E. Pleiotropic consequences of gene knockouts in the phthiocerol dimycocerosate and phenolic glycolipid biosynthetic gene cluster of the opportunistic human pathogen *Mycobacterium marinum*. *FEMS Microbiol. Lett.* **2016**, *363*, fnw016. [[CrossRef](#)]
22. Nguyen, P.C.; Nguyen, V.S.; Martin, B.P.; Fourquet, P.; Camoin, L.; Spilling, C.D.; Cavalier, J.F.; Cambillau, C.; Canaan, S. Biochemical and Structural Characterization of TesA, a Major Thioesterase Required for Outer-Envelope Lipid Biosynthesis in *Mycobacterium tuberculosis*. *J. Mol. Biol.* **2018**, *430*, 5120–5136. [[CrossRef](#)]
23. Snewin, V.A.; Gares, M.P.; Gaora, P.O.; Hasan, Z.; Brown, I.N.; Young, D.B. Assessment of immunity to mycobacterial infection with luciferase reporter constructs. *Infect. Immun.* **1999**, *67*, 4586–4593. [[CrossRef](#)] [[PubMed](#)]
24. Hsieh, M.H.; Yu, C.M.; Yu, V.L.; Chow, J.W. Synergy assessed by checkerboard. A critical analysis. *Diagn. Microbiol. Infect. Dis.* **1993**, *16*, 343–349. [[CrossRef](#)] [[PubMed](#)]
25. Deschoenmaeker, F.; Bayon-Vicente, G.; Sachdeva, N.; Depraetere, O.; Cabrera Pino, J.C.; Leroy, B.; Muylaert, K.; Wattiez, R. Impact of different nitrogen sources on the growth of *Arthrospira* sp. PCC 8005 under batch and continuous cultivation—A biochemical, transcriptomic and proteomic profile. *Bioresour. Technol.* **2017**, *237*, 78–88. [[CrossRef](#)] [[PubMed](#)]
26. Xiao, H.; Zhang, Y.; Kim, Y.; Kim, S.; Kim, J.J.; Kim, K.M.; Yoshizawa, J.; Fan, L.Y.; Cao, C.X.; Wong, D.T. Differential Proteomic Analysis of Human Saliva using Tandem Mass Tags Quantification for Gastric Cancer Detection. *Sci. Rep.* **2016**, *6*, 22165. [[CrossRef](#)]
27. Xu, C.G.; Yang, Y.B.; Zhou, Y.H.; Hao, M.Q.; Ren, Y.Z.; Wang, X.T.; Chen, J.Q.; Muhammad, I.; Wang, S.; Liu, D.; et al. Comparative Proteomic Analysis Provides insight into the Key Proteins as Possible Targets Involved in Aspirin Inhibiting Biofilm Formation of *Staphylococcus xylosus*. *Front. Pharmacol.* **2017**, *8*, 543. [[CrossRef](#)]
28. Cortes, T.; Schubert, O.T.; Rose, G.; Arnvig, K.B.; Comas, I.; Aebersold, R.; Young, D.B. Genome-wide mapping of transcriptional start sites defines an extensive leaderless transcriptome in *Mycobacterium tuberculosis*. *Cell Rep.* **2013**, *5*, 1121–1131. [[CrossRef](#)]
29. Yu, J.; Tran, V.; Li, M.; Huang, X.; Niu, C.; Wang, D.; Zhu, J.; Wang, J.; Gao, Q.; Liu, J. Both phthiocerol dimycocerosates and phenolic glycolipids are required for virulence of *Mycobacterium marinum*. *Infect. Immun.* **2012**, *80*, 1381–1389. [[CrossRef](#)]
30. Lamprecht, D.A.; Finin, P.M.; Rahman, M.A.; Cumming, B.M.; Russell, S.L.; Jonnala, S.R.; Adamson, J.H.; Steyn, A.J. Turning the respiratory flexibility of *Mycobacterium tuberculosis* against itself. *Nat. Commun.* **2016**, *7*, 12393. [[CrossRef](#)]

31. Wang, Z.; Soni, V.; Marriner, G.; Kaneko, T.; Boshoff, H.I.M.; Barry, C.E., 3rd; Rhee, K.Y. Mode-of-action profiling reveals glutamine synthetase as a collateral metabolic vulnerability of *M. tuberculosis* to bedaquiline. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 19646–19651. [[CrossRef](#)]
32. Mackenzie, J.S.; Lamprecht, D.A.; Asmal, R.; Adamson, J.H.; Borah, K.; Beste, D.J.V.; Lee, B.S.; Pethe, K.; Rousseau, S.; Krieger, I.; et al. Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in *Mycobacterium tuberculosis*. *Nat. Commun.* **2020**, *11*, 6092. [[CrossRef](#)] [[PubMed](#)]
33. Kalia, N.P.; Hasenoehrl, E.J.; Ab Rahman, N.B.; Koh, V.H.; Ang, M.L.T.; Sajorda, D.R.; Hards, K.; Gruber, G.; Alonso, S.; Cook, G.M.; et al. Exploiting the synthetic lethality between terminal respiratory oxidases to kill *Mycobacterium tuberculosis* and clear host infection. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 7426–7431. [[CrossRef](#)] [[PubMed](#)]
34. Lupien, A.; Foo, C.S.; Savina, S.; Vocat, A.; Piton, J.; Monakhova, N.; Benjak, A.; Lamprecht, D.A.; Steyn, A.J.C.; Pethe, K.; et al. New 2-Ethylthio-4-methylaminoquinazoline derivatives inhibiting two subunits of cytochrome *bc₁* in *Mycobacterium tuberculosis*. *PLoS Pathog.* **2020**, *16*, e1008270. [[CrossRef](#)] [[PubMed](#)]
35. Betts, J.C.; Lukey, P.T.; Robb, L.C.; McAdam, R.A.; Duncan, K. Evaluation of a nutrient starvation model of *Mycobacterium tuberculosis* persistence by gene and protein expression profiling. *Mol. Microbiol.* **2002**, *43*, 717–731. [[CrossRef](#)] [[PubMed](#)]
36. Gengenbacher, M.; Rao, S.P.S.; Pethe, K.; Dick, T. Nutrient-starved, non-replicating *Mycobacterium tuberculosis* requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. *Microbiology* **2010**, *156*, 81–87. [[CrossRef](#)]
37. Koul, A.; Vranckx, L.; Dhar, N.; Gohlmann, H.W.; Ozdemir, E.; Neefs, J.M.; Schulz, M.; Lu, P.; Mortz, E.; McKinney, J.D.; et al. Delayed bactericidal response of *Mycobacterium tuberculosis* to bedaquiline involves remodelling of bacterial metabolism. *Nat. Commun.* **2014**, *5*, 3369. [[CrossRef](#)]
38. Flentie, K.N.; Stallings, C.L.; Turk, J.; Minnaard, A.J.; Hsu, F.F. Characterization of phthiocerol and phthiodiolone dimycocerosate esters of *M. tuberculosis* by multiple-stage linear ion-trap MS. *J. Lipid. Res.* **2016**, *57*, 142–155. [[CrossRef](#)]
39. Block, A.M.; Namugenyi, S.B.; Palani, N.P.; Brokaw, A.M.; Zhang, L.; Beckman, K.B.; Tischler, A.D. *Mycobacterium tuberculosis* Requires the Outer Membrane Lipid Phthiocerol Dimycocerosate for Starvation-Induced Antibiotic Tolerance. *mSystems* **2023**, *8*, e0069922. [[CrossRef](#)]
40. Woodworth, J.S.; Clemmensen, H.S.; Battey, H.; Dijkman, K.; Lindstrom, T.; Laureano, R.S.; Taplitz, R.; Morgan, J.; Aagaard, C.; Rosenkrands, I.; et al. A *Mycobacterium tuberculosis*-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guerin. *Nat. Commun.* **2021**, *12*, 6658. [[CrossRef](#)]
41. Cambier, C.J.; Takaki, K.K.; Larson, R.P.; Hernandez, R.E.; Tobin, D.M.; Urdahl, K.B.; Cosma, C.L.; Ramakrishnan, L. Mycobacteria manipulate macrophage recruitment through coordinated use of membrane lipids. *Nature* **2014**, *505*, 218–222. [[CrossRef](#)]
42. de Jager, V.R.; Dawson, R.; van Niekerk, C.; Hutchings, J.; Kim, J.; Vanker, N.; van der Merwe, L.; Choi, J.; Nam, K.; Diacon, A.H. Telacebec (Q203), a New Antituberculosis Agent. *N. Engl. J. Med.* **2020**, *382*, 1280–1281. [[CrossRef](#)] [[PubMed](#)]
43. Slayden, R.A.; Knudson, D.L.; Belisle, J.T. Identification of cell cycle regulators in *Mycobacterium tuberculosis* by inhibition of septum formation and global transcriptional analysis. *Microbiology* **2006**, *152*, 1789–1797. [[CrossRef](#)] [[PubMed](#)]
44. Mavrici, D.; Marakalala, M.J.; Holton, J.M.; Prigozhin, D.M.; Gee, C.L.; Zhang, Y.J.; Rubin, E.J.; Alber, T. *Mycobacterium tuberculosis* FtsX extracellular domain activates the peptidoglycan hydrolase, RipC. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 8037–8042. [[CrossRef](#)] [[PubMed](#)]
45. Parthasarathy, G.; Lun, S.; Guo, H.; Ammerman, N.C.; Geiman, D.E.; Bishai, W.R. Rv2190c, an NlpC/P60 family protein, is required for full virulence of *Mycobacterium tuberculosis*. *PLoS ONE* **2012**, *7*, e43429. [[CrossRef](#)] [[PubMed](#)]
46. Park, H.D.; Guinn, K.M.; Harrell, M.I.; Liao, R.; Voskuil, M.I.; Tompa, M.; Schoolnik, G.K.; Sherman, D.R. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of *Mycobacterium tuberculosis*. *Mol. Microbiol.* **2003**, *48*, 833–843. [[CrossRef](#)]
47. Boon, C.; Dick, T. *Mycobacterium bovis* BCG response regulator essential for hypoxic dormancy. *J. Bacteriol.* **2002**, *184*, 6760–6767. [[CrossRef](#)]
48. Zheng, H.; Colvin, C.J.; Johnson, B.K.; Kirchhoff, P.D.; Wilson, M.; Jorgensen-Muga, K.; Larsen, S.D.; Abramovitch, R.B. Inhibitors of *Mycobacterium tuberculosis* DosRST signaling and persistence. *Nat. Chem. Biol.* **2017**, *13*, 218–225. [[CrossRef](#)]
49. Kaur, D.; Kutum, R.; Dash, D.; Brahmachari, S.K. Data Intensive Genome Level Analysis for Identifying Novel, Non-Toxic Drug Targets for Multi Drug Resistant *Mycobacterium tuberculosis*. *Sci. Rep.* **2017**, *7*, 46595. [[CrossRef](#)]
50. Zhang, S.; Chen, J.; Shi, W.; Liu, W.; Zhang, W.; Zhang, Y. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in *Mycobacterium tuberculosis*. *Emerg. Microbes. Infect.* **2013**, *2*, e34. [[CrossRef](#)]
51. Leonardi, R.; Jackowski, S. Biosynthesis of Pantothenic Acid and Coenzyme A. *EcoSal. Plus* **2007**, *2*, 10–1128. [[CrossRef](#)]
52. Foo, C.S.; Lupien, A.; Kienle, M.; Vocat, A.; Benjak, A.; Sommer, R.; Lamprecht, D.A.; Steyn, A.J.C.; Pethe, K.; Piton, J.; et al. Arylvinyloxy piperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of *Mycobacterium tuberculosis*. *mBio* **2018**, *9*, e01276–18. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.